{"schema_version":"secwatch.filing_event.v1","accession":"0001082554-23-000024","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.096219+00:00","generated_at":"2026-06-12T11:19:11.192587+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"United Therapeutics Q2 2023: revenue $596.5M (+28%), net income $259.2M (+123%)","bullets":["Total revenues $596.5M (+28% YoY), net income $259.2M (+123%), diluted EPS $5.24.","Tyvaso (including DPI) sales $318.9M, up 59% YoY, driven by patient growth and inventory build.","Orenitram sales $95.1M (+20%); Remodulin sales $127.2M (-4% YoY).","CEO expects $4B annual revenue run rate by mid-decade with continued expansion.","Share-based comp expense fell 79% to $13.8M due to stock price performance."],"urls":{"canonical":"https://secwatch.observer/filing/0001082554-23-000024","json":"https://secwatch.observer/filing/0001082554-23-000024.json","markdown":"https://secwatch.observer/filing/0001082554-23-000024.md","text":"https://secwatch.observer/filing/0001082554-23-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000108255423000024/0001082554-23-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000108255423000024/uthr-20230802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T11:19:11.192587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ad567ba3374195f34fcf043638df2dd15780fa1","claim":"UNITED THERAPEUTICS Corp reported the quarter ended June 30, 2023 results: revenue $596.5 million, net income $259.2 million, EPS $5.24 per diluted share. Guidance reaffirmed.","evidence_excerpt":"Total revenues in the second quarter of 2023 grew 28% year-over-year to $596.5 million, compared to $466.9 million in the second quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1082554/000108255423000024/0001082554-23-000024-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$596.5 million"},{"label":"Net income","value":"$259.2 million"},{"label":"EPS","value":"$5.24 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}